Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Feb 24;20(1):31.
doi: 10.1007/s11657-025-01512-9.

Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis

N V Grygorieva  1 , V M Kovalenko  2 , M O Кorzh  3   4 , M D Tronko  5 , I Yu Golovach  6 , N V Dedukh  7 , D G Rekalov  2 , S S Strafun  8 , S I Smiyan  9 , O A Golubovska  10 , Ya O Dziublyk  11 , N V Kharchenko  12 , G O Protsenko  2 , O O Garmish  2 , V L Orlenko  5 , F V Klymovytskyy  13 , A S Musiienko  7 , T A Karasevska  10 ; Ukrainian Association of Osteoporosis
Affiliations
Practice Guideline

Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis

N V Grygorieva et al. Arch Osteoporos. .

Abstract

Introduction: Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disorder caused by glucocorticoid (GC) use. It is one of the leading causes of secondary osteoporosis, increasing the risk of low-energy fractures, disability, and mortality. Although limited studies on GIOP epidemiology and treatment have been conducted in Ukraine, there were no national guidelines for its management. The aim was to create national guideline for the GIOP diagnosis, prevention, and treatment based on a comprehensive review of modern literature to enhance awareness within Ukraine's medical community, improve disease management, and reduce its socio-economic impact.

Materials and methods: An Expert Group comprising 18 leading Ukrainian scientists from various fields was created for guideline development. A review of modern literature on GIOP epidemiology, risk factors, diagnosis, prevention, treatment, and monitoring was conducted. Evidence synthesis followed the GRADE methodology, and the quality of recommendations was critically evaluated using the AGREE II tool.

Results: The guideline comprises 12 statements covering GIOP screening, diagnosis, prevention, and treatment. We highlight the need to raise awareness among healthcare providers and patients about the potential effects of GC therapy. Also, we outline approaches to clinical assessment of osteoporotic fracture risk in GC users and detail diagnostic and therapeutic methods currently available in Ukraine for managing GIOP.

Conclusion: The first Ukrainian national GIOP guideline is critical for healthcare providers across specialities. Endorsed by the Board of the Ukrainian Association of Osteoporosis, it is recommended for use in routine clinical practice to enhance patient outcomes and mitigate the disease's impact.

Keywords: Diagnosis; Glucocorticoid-induced osteoporosis; Guideline; Prevention; Recommendations; Treatment.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: None.

References

    1. International Osteoporosis Foundation. About osteoporosis. Available from: https://www.osteoporosis.foundation/health-professionals/about-osteoporosis . Accessed: 2024.12.25
    1. Xiao PL, Cui AY, Hsu CJ et al (2022) Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis. Osteoporos Int 33(10):2137–2153. https://doi.org/10.1007/s00198-022-06454-3 - DOI - PubMed
    1. Soen S, Kaku M, Okubo N, Touzeni S, Saito K, Kobayashi M (2021) Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan. J Bone Miner Metab 39(6):1019–1030. https://doi.org/10.1007/s00774-021-01236-z - DOI - PubMed
    1. Ma CC, Xu SQ, Gong X et al (2017) Prevalence and risk factors associated with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis. Arch Osteoporos 12(1):33. https://doi.org/10.1007/s11657-017-0329-0 - DOI - PubMed
    1. Amiche MA, Albaum JM, Tadrous M et al (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27(5):1709–18. https://doi.org/10.1007/s00198-015-3455-9 - DOI - PubMed

Publication types

Substances

LinkOut - more resources